Leading specialty drug manufacturer to advance compliance, oversight, and inspection readiness with Veeva QualityDocs and Veeva Training<\/i><\/p>\n
BARCELONA, Spain \u2014 25 July 2024 \u2014 <\/strong> Veeva Systems<\/a> (NYSE: VEEV) today announced that Neuraxpharm<\/a> will use Veeva QualityDocs<\/a> and Veeva Training<\/a> to advance its quality operations. Veeva quality applications will help Neuraxpharm achieve greater oversight and inspection readiness, while improving collaboration across its network of over 100 contract development and manufacturing organizations (CDMOs).<\/p>\n \u201cVeeva Quality Cloud enables Neuraxpharm to bring GxP documentation and quality training onto one platform making quality operations more efficient and scalable,\u201d said Susanne Cater, head of corporate quality at Neuraxpharm. \u201cWith Veeva QualityDocs and Veeva Training, we can advance quality document management and compliance, including how we work with CDMOs.\u201d<\/p>\n Neuraxpharm is a pharmaceutical leader in disorders affecting the central nervous system (CNS). Veeva QualityDocs supports efficient GxP content management and information sharing across its sites, while Veeva Training enables Neuraxpharm to deploy training and curricula to help ensure GxP compliance. <\/p>\n \u201cWith Veeva Quality Cloud, Neuraxpharm can streamline content and training, enabling the company to scale as it expands its product portfolio,\u201d said Sofia Lange, director of quality strategy for Europe at Veeva. \u201cWe\u2019re excited to partner with Neuraxpharm in advancing quality across its organization and keep production of vital CNS treatments for patients on track.\u201d<\/p>\n Additional Information<\/strong> About Veeva Systems<\/strong> Veeva Forward-looking Statements<\/strong> ###<\/p>\n
\nFor more on Veeva Quality Cloud, visit: veeva.com\/eu\/VaultQuality<\/a>
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>\n<\/p>\n
\nVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world\u2019s largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation<\/a>, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com\/eu<\/a>.<\/p>\n
\nThis release contains forward-looking statements regarding Veeva\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2024, which you can find here<\/a> (a summary of risks which may impact our business can be found on pages 35 and 36), and in our subsequent SEC filings, which you can access at sec.gov<\/a>.<\/p>\n